Gender equality in the biotech industry has come a long way in recent years. In the UK, the US and Europe, women now make up between 40-50% of the biotech workforce, which is a higher percentage than in other STEM fields, such as engineering and the physical sciences.
ImmuONE made a significant stride on November 8th by hosting its first-ever webinar, ‘unveiling insights into the next generation of tools for inhalation risk assessment’. The webinar began with a glimpse into ImmuONE’s evolution, emphasizing key milestones and leadership perspectives, presented by Prof. Victoria Hutter.
In our most recent coffee chat, we caught up with Jo Kelsall, our new lead commercial scientist. Jo shared with us her unique career spanning the realms of science and law while also giving us the inside scoop on what life has been like so far at ImmuONE!
Dr Abigail Martin and Professor Victoria Hutter have secured backing from the MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia Ventures and part of the Midlands Engine Investment Fund (MEIF), Mercia’s EIS funds and Pioneer Group.
In our latest coffee chat, we had the pleasure of sitting down with Rhamiya Mahendran, an Application Scientist at ImmuONE…
Inhaled substances are primarily tested on rats for toxicity, but key differences between rat and human lungs suggest it’s time to look towards alternative methods.
morph_ONE is a reproducible, mechanistic-driven assay that reveals how inhaled substances affect more than a dozen morphological and biochemical features of alveolar macrophages. The assay helps companies and researchers to correctly interpret the response of the immune system in the lungs to inhaled chemical products, improving product development and ensuring safety as well as saving time and money.
More than half of aerosol medicines under development are terminated due to safety concerns. ImmuONE’s high content imaging or cell painting assays are proven to accurately predict the safety of inhaled compounds by quantifying mechanism-linked morphological and biochemical characteristics within cells, contributing to faster, more informed decision making in the early stages of inhaled drug development.
Q: What attracted you to ImmuONE as a company?
A: I was initially drawn to ImmuONE because of my positive experience during my final year dissertation, where I worked on cell culture skills with Dr. Victoria Hutter…